Klaus A. Dugi

Medicine · Health Sciences

43h-index5.5kcitations95works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(30), Pancreatic function and diabetes(21), Lipid metabolism and disorders(16), Diabetes, Cardiovascular Risks, and Lipoproteins(15), Metabolism, Diabetes, and Cancer(15)

Publications95 total

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Circulation·2021· 141 citedOpen Access
Analysis of Protein Structure-Function in Vivo: ADENOVIRUS-MEDIATED TRANSFER OF LIPASE LID MUTANTS IN HEPATIC LIPASE-DEFICIENT MICE
UNC Libraries·2021· 1 citedOpen Access
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer
JACC CardioOncology·2020· 48 citedOpen Access
The Boehringer Ingelheim employee study (Part 2): 10-year cardiovascular diseases risk estimation
Occupational Medicine·2016· 5 cited
Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status
American Journal of Clinical Nutrition·2015· 31 citedOpen Access
Dosing Recommendations for New Oral Anticoagulants
JAMA·2015
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial
Diabetes Obesity and Metabolism·2014· 10 cited
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
Diabetologia·2014· 60 citedOpen Access
The dipeptidyl peptidase‐4 inhibitor linagliptin lowers postprandial glucose and improves measures of <i>β</i> ‐cell function in type 2 diabetes
Diabetes Obesity and Metabolism·2014· 12 cited
Association between a gene variant near ataxia telangiectasia mutated and coronary artery disease in men
Diabetes and Vascular Disease Research·2013· 12 citedOpen Access
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Diabetes Therapy·2013· 118 citedOpen Access
Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects
Clinical Pharmacology in Drug Development·2013· 134 cited
The Epidemiological Boehringer Ingelheim Employee Study—Part I: Impact of Overweight and Obesity on Cardiometabolic Risk
Journal of Obesity·2013· 13 citedOpen Access
Long‐term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes
Diabetes Obesity and Metabolism·2012· 28 cited
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects
Drug Metabolism and Pharmacokinetics·2012· 84 cited
Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
Diabetes Therapy·2012· 51 citedOpen Access
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
The Lancet·2012· 336 cited
Die Gutenberg Gesundheitsstudie
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz·2012· 230 cited
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator‐controlled, double‐blind study
Diabetes Obesity and Metabolism·2011· 109 cited
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24‐week randomized study<sup>1</sup>
Diabetic Medicine·2011· 211 cited
page 1 of 5Next →

Frequent Co-authors

Silvia Santamarina-Fojo(12), Arne Ring(9), Peter P. Nawroth(9), Maximilian von Eynatten(8), Hans J. Woerle(7), H. Bryan Brewer(7), Eva U. Graefe-Mody(6), A. Hamann(6), Jochen G. Schneider(6), Ulrike Graefe‐Mody(6), Hans‐Juergen Woerle(5), Angelika Bierhaus(5), Per M. Humpert(4), Joerg Kreuzer(4), Akiko Sarashina(4), Tim Heise(3), S. Hüttner(3), Leo Seman(3), Glenda D. Talley(3), André Bensadoun(3)